Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of JPY 308.69 billion. The enterprise value is 597.72 billion.

Market Cap	308.69B
Enterprise Value	597.72B

Important Dates

The last earnings date was Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Sumitomo Pharma has 397.29 million shares outstanding. The number of shares has decreased by -0.00% in one year.

Current Share Class	n/a
Shares Outstanding	397.29M
Shares Change (YoY)	-0.00%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	0.06%
Owned by Institutions (%)	15.34%
Float	180.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	26.24
PS Ratio	0.83
PB Ratio	1.86
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.40
EV / Sales	1.60
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-37.19

Financial Position

The company has a current ratio of 0.67, with a Debt / Equity ratio of 2.25.

Current Ratio	0.67
Quick Ratio	0.37
Debt / Equity	2.25
Debt / EBITDA	n/a
Debt / FCF	-23.30
Interest Coverage	-29.53

Financial Efficiency

Return on equity (ROE) is -69.06% and return on invested capital (ROIC) is -21.62%.

Return on Equity (ROE)	-69.06%
Return on Assets (ROA)	-14.65%
Return on Invested Capital (ROIC)	-21.62%
Return on Capital Employed (ROCE)	-63.54%
Revenue Per Employee	74.84M
Profits Per Employee	-35.35M
Employee Count	4,980
Asset Turnover	0.39
Inventory Turnover	1.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +114.17% in the last 52 weeks. The beta is 0.61, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+114.17%
50-Day Moving Average	629.10
200-Day Moving Average	530.97
Relative Strength Index (RSI)	66.84
Average Volume (20 Days)	3,940,725

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of JPY 372.71 billion and -176.04 billion in losses. Loss per share was -443.11.

Revenue	372.71B
Gross Profit	225.56B
Operating Income	-224.17B
Pretax Income	-193.90B
Net Income	-176.04B
EBITDA	-194.91B
EBIT	-224.17B
Loss Per Share	-443.11

Full Income Statement

Balance Sheet

The company has 85.39 billion in cash and 374.42 billion in debt, giving a net cash position of -289.03 billion or -727.50 per share.

Cash & Cash Equivalents	85.39B
Total Debt	374.42B
Net Cash	-289.03B
Net Cash Per Share	-727.50
Equity (Book Value)	166.12B
Book Value Per Share	418.12
Working Capital	-165.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.67 billion and capital expenditures -10.40 billion, giving a free cash flow of -16.07 billion.

Operating Cash Flow	-5.67B
Capital Expenditures	-10.40B
Free Cash Flow	-16.07B
FCF Per Share	-40.46

Full Cash Flow Statement

Margins

Gross margin is 60.52%, with operating and profit margins of -60.14% and -47.23%.

Gross Margin	60.52%
Operating Margin	-60.14%
Pretax Margin	-52.02%
Profit Margin	-47.23%
EBITDA Margin	-52.29%
EBIT Margin	-60.14%
FCF Margin	n/a

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.00%
Shareholder Yield	0.00%
Earnings Yield	-57.03%
FCF Yield	-5.21%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of -0.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.43
Piotroski F-Score	n/a